<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578367</url>
  </required_header>
  <id_info>
    <org_study_id>CABL001E2201</org_study_id>
    <secondary_id>2018-001594-24</secondary_id>
    <nct_id>NCT03578367</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)</brief_title>
  <official_title>A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or&#xD;
      asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated&#xD;
      patients with Chronic Myeloid Leukemia in chronic phase (CML-CP)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Phase 2, multi-center, open-label, randomized study of asciminib in two&#xD;
      different doses (40 mg or 60 mg) in combination with imatinib 400 mg versus continued&#xD;
      imatinib versus switch to nilotinib in subjects with chronic myeloid leukemia in chronic&#xD;
      phase (CML-CP) who have been previously treated with imatinib first line therapy for at least&#xD;
      one year and have not achieved deep molecular response (DMR). The eligible subjects will be&#xD;
      randomized 1:1:1:1 to receive asciminib 60 mg QD as add-on therapy to imatinib 400 mg QD, or&#xD;
      40 mg QD as add-on therapy to imatinib 400 mg QD, or to continue imatinib 400 mg QD, or to&#xD;
      switch to nilotinib 300 mg twice a day (BID).&#xD;
&#xD;
      Subjects on the study will continue on the allocated treatment until treatment failure,&#xD;
      intolerability, or for up to 96 weeks after the last randomized subject received the first&#xD;
      dose of treatment (the end of treatment (EOT) will be the same day for all the ongoing&#xD;
      subjects). After the last dose received, every subject will be followed up for safety for 30&#xD;
      days.&#xD;
&#xD;
      An interim analysis will be performed when at least 40 (50%) patients have been randomized&#xD;
      and have been followed for their 24 weeks visit assessment or have discontinued treatment. At&#xD;
      the time of the interim analysis, if excessive toxicity without added benefit is observed in&#xD;
      one of the investigational arms, discontinuation of that treatment arm will be considered.&#xD;
      The decision to discontinue an investigational arm in the study will be taken based on the&#xD;
      risk benefit balance of the two investigational arms, and in context of the other two&#xD;
      treatment options available for the patients in the study, namely: continue on imatinib with&#xD;
      no potential improvement of efficacy; or switch to nilotonib with a potential to improve&#xD;
      efficacy however, with a relatively adverse safety profile as compared to imatinib. If a&#xD;
      decision is taken to discontinue asciminib 60 mg + imatinib treatment arm at interim&#xD;
      analysis, subjects ongoing on that treatment arm will be provided an opportunity to continue&#xD;
      on the study at a lower dose (asciminib 40 mg + imatinib) if the investigator considers that&#xD;
      is in the best interest of the patient.&#xD;
&#xD;
      Subjects on the imatinib continuation arm who have not achieved MR4.5 at 48 weeks may&#xD;
      cross-over (CO) to receive the add-on treatment within 4 weeks after week 48 visit. It is&#xD;
      planned that these subjects cross-over to receive the asciminib 60 mg combination add-on&#xD;
      treatment, as this dose provides higher exposure. Based on the results of the interim&#xD;
      analysis or emerging data, cross-over may be changed to the asciminib 40 mg add-on treatment.&#xD;
      The cross-over is at the discretion of the investigator and the patient. Apart from a&#xD;
      polymerase chain reaction (PCR) result of below MR4.5 at Week 48 visit, there are no other&#xD;
      entry criteria for the cross-over part. Subjects on nilotinib are not allowed to cross- over&#xD;
      to receive the add-on treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 22, 2018</start_date>
  <completion_date type="Anticipated">November 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular Response (MR)^4.5 rate between asciminib+imatinib and imatinib alone</measure>
    <time_frame>at 48 weeks</time_frame>
    <description>Proportion of subjects still treated with the randomized treatment at 48 weeks and are in MR4.5 (BCR-ABL1 ratio of ≤ 0.0032%) at 48 weeks (± assessment window), among all subjects randomized to the respective treatment arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MR^4.5 rate at 48 weeks</measure>
    <time_frame>at 48 weeks</time_frame>
    <description>Difference in the proportion of subjects with MR^4.5 (BCR-ABL1 ratio of ≤ 0.0032%) at 48 weeks between asciminib+imatinib and nilotinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MR^4.5 at 96 weeks</measure>
    <time_frame>at 96 weeks</time_frame>
    <description>Proportion of subjects with MR^4.5 (BCR-ABL1 ratio of ≤ 0.0032%) at 96 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MR^4.5 by 48 and 96 weeks</measure>
    <time_frame>by 48 weeks and 96 weeks</time_frame>
    <description>Best observed rate of MR^4.5 (BCR-ABL1 ratio of ≤ 0.0032%) under randomized treatment up to the specific time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained MR^4.5 from 48 weeks until 96 weeks</measure>
    <time_frame>from 48 weeks until 96 weeks</time_frame>
    <description>Percentage of participants who are in MR^4.5 (BCR-ABL1 ratio of ≤ 0.0032%) at both 48 and 96 weeks and who have no loss of MR^4.5 in between those two time points. This endpoint will be analyzed at 96 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to MR^4.5</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Time to MR^4.5 is the time from randomization to first MR^4.5 (BCR-ABL1 ratio of ≤ 0.0032%) computed only for subjects who achieved MR^4.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in rate of MR^4.5 at 48 weeks</measure>
    <time_frame>at 48 weeks</time_frame>
    <description>Difference in the proportion of subjects with MR^4.5 (BCR-ABL1 ratio of ≤ 0.0032%) at 48 weeks between asciminib+imatinib and nilotinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of asciminib and imatinib when administered in combination - Cmax</measure>
    <time_frame>up to Week 4 Day 28</time_frame>
    <description>The maximum (peak) observed drug concentration after dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of asciminib and imatinib when administered in combination - Tmax</measure>
    <time_frame>up to Week 4 Day 28</time_frame>
    <description>The time to reach maximum (peak) drug concentration after dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of asciminib and imatinib when administered in combination - Cmin</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Minimum drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of asciminib and imatinib when administered in combination - AUClast</measure>
    <time_frame>up to Week 4 Day 28</time_frame>
    <description>The AUC from time zero to the last measurable concentration sampling time (Tlast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of asciminib and imatinib when administered in combination - AUCtau</measure>
    <time_frame>up to Week 4 Day 28</time_frame>
    <description>The AUC calculated to the end of a dosing interval (tau) at steady-state</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>CML</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Leukemia, Myeloid Chronic</condition>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Asciminib 60mg QD + Imatinib 400mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asciminib 40mg QD + Imatinib 400mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib 400mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imatinib 400 mg taken once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilotinib 300mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nilotinib 300 mg taken twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asciminib add-on</intervention_name>
    <description>Asciminib 60 mg or 40 mg taken orally once daily in addition to Imatinib 400 mg taken orally once daily</description>
    <arm_group_label>Asciminib 40mg QD + Imatinib 400mg QD</arm_group_label>
    <arm_group_label>Asciminib 60mg QD + Imatinib 400mg QD</arm_group_label>
    <other_name>ABL001 (asciminib), STI571 (imatinib)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Imatinib 400 mg taken orally once daily</description>
    <arm_group_label>Imatinib 400mg QD</arm_group_label>
    <other_name>STI571, continuation treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)</description>
    <arm_group_label>Nilotinib 300mg BID</arm_group_label>
    <other_name>AMN107, switch to nilotinib treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥ 18 years of age with a confirmed diagnosis of Chronic&#xD;
             Myeloid Leukemia in chronic phase (CML-CP).&#xD;
&#xD;
          2. Minimum of one year (12 calendar months) treatment with imatinib first line for CML-CP&#xD;
             (patients have to be on imatinib 400 mg QD at randomization and had no dose change in&#xD;
             the past three months).&#xD;
&#xD;
             For Korea only: (i)a minimum of one year (12 calendar months) of prior treatment with&#xD;
             imatinib for patients with BCR-ABL levels &gt; 0.1%, ≤ 1% IS at the time of&#xD;
             randomization. (ii) a minimum of two years (24 calendar months) of prior treatment&#xD;
             with imatinib for patients with BCR-ABL levels &gt; 0.01%, ≤ 0.1% IS at the time of&#xD;
             randomization.&#xD;
&#xD;
          3. BCR-ABL1 levels &gt; 0.01% IS (International Scale) and ≤ 1% IS at the time of&#xD;
             randomization as confirmed with a central assessment at screening; patients must not&#xD;
             have achieved deep molecular response (MR4 IS) confirmed by 2 consecutive tests at any&#xD;
             time during prior imatinib treatment. An isolated, single test result with BCR-ABL1&#xD;
             levels &lt; 0.01 % (MR4 IS) is allowed, however, it should not have been observed within&#xD;
             the 9 months prior to randomization&#xD;
&#xD;
          4. Patient must meet the following laboratory values before randomization:&#xD;
&#xD;
               -  Absolute Neutrophil Count ≥ 1.5 x 10E9/L&#xD;
&#xD;
               -  Platelets ≥ 75 x 10E9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN (Upper Limit of Normal) except for patients with&#xD;
                  Gilbert's syndrome who may only be included with total bilirubin ≤ 3.0 x ULN&#xD;
&#xD;
               -  Aspartate transaminase (AST) ≤ 3.0 x ULN&#xD;
&#xD;
               -  Alanine transaminase (ALT) ≤ 3.0 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
               -  Serum lipase ≤ 1.5 x ULN&#xD;
&#xD;
          5. Patients must have the following laboratory values ≥ Lower Limit of Normal or&#xD;
             corrected to within normal limits with supplements prior to randomization: potassium&#xD;
             increase of up to 6.0 mmol/L is acceptable if associated with creatinine clearance&#xD;
             within normal limits ; calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is&#xD;
             acceptable if associated with creatinine clearance* within normal limits) ; magnesium&#xD;
             increase up to 3.0 mg/dL or 1.23 mmol/L if associated with creatinine clearance within&#xD;
             normal limits.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Treatment failure according to European Leukemia Network (ELN) criteria 2013 during&#xD;
             imatinib treatment.&#xD;
&#xD;
          2. Known second chronic phase of CML after previous progression to Accelerated Phase&#xD;
             (AP)/Blast Crisis (BC).&#xD;
&#xD;
          3. Previous treatment with any tyrosine kinese inhibitors (TKIs) other than imatinib.&#xD;
&#xD;
          4. History or current diagnosis of ECG abnormalities indicating significant risk or&#xD;
             safety for subjects participating in the study such as:&#xD;
&#xD;
               -  History of myocardial infarction, angina pectoris, coronary artery bypass graft&#xD;
                  within 6 months prior to randomization&#xD;
&#xD;
               -  Concomitant clinically significant arrhythmias&#xD;
&#xD;
               -  Resting QTcF ≥ 450 msec (male) or ≥ 460 msec (female) prior to randomization&#xD;
&#xD;
               -  Long QT syndrome, family history of idiopathic sudden death or congenital long QT&#xD;
                  syndrome, or any of the following:&#xD;
&#xD;
                    -  Risk factors for Torsades de Pointes&#xD;
&#xD;
                    -  Concomitant medications with a &quot;known&quot; risk of Torsades de Pointes&#xD;
&#xD;
                    -  inability to determine the QTcF interval&#xD;
&#xD;
          5. Severe and/or uncontrolled concurrent medical disease that in the opinion of the&#xD;
             investigator could cause unacceptable safety risks or compromise compliance with the&#xD;
             protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled&#xD;
             clinically significant hyperlipidemia and high serum amylase)&#xD;
&#xD;
          6. History of acute pancreatitis within 1 year prior to randomization or medical history&#xD;
             of chronic pancreatitis; on-going acute liver disease or history of chronic liver&#xD;
             disease&#xD;
&#xD;
          7. History of other active malignancy within 3 years prior to randomization with the&#xD;
             exception of basal cell skin cancer, indolent prostate cancer and carcinoma in situ&#xD;
             treated curatively.&#xD;
&#xD;
        Other protocol defined inclusion/exclusion may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno - Bohunice</city>
        <zip>639 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herlev</city>
        <zip>DK 2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seocho Gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31 531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02 776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50 367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1099 023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>50006</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wirral</city>
        <state>Merseyside</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>Hong Kong</country>
    <country>Japan</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>leukemia, myeloid chronic</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Asciminib</keyword>
  <keyword>ABL001</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>deep molecular response</keyword>
  <keyword>DMR</keyword>
  <keyword>Ph+ CML</keyword>
  <keyword>chronic phase</keyword>
  <keyword>cancer of the white blood cells</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>leukemia, myeloid</keyword>
  <keyword>leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

